Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits.
Fernández A, Pérez-Martínez A, Escudero A, Mirones I, González B, de Paz R, Matamala N, Clares L, Navarro A, Galán V, Martínez-Romera I, Martínez-López J, Leivas A, Valés-Gómez M, Ferreras C, Fernández L. Fernández A, et al. Leuk Lymphoma. 2022 Aug;63(8):1970-1974. doi: 10.1080/10428194.2022.2057490. Epub 2022 Apr 3. Leuk Lymphoma. 2022. PMID: 35369829 No abstract available.
Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
Vela M, Corral D, Carrasco P, Fernández L, Valentín J, González B, Escudero A, Balas A, de Paz R, Torres J, Leivas A, Martinez-Lopez J, Pérez-Martínez A. Vela M, et al. Cancer Lett. 2018 May 28;422:107-117. doi: 10.1016/j.canlet.2018.02.033. Epub 2018 Feb 23. Cancer Lett. 2018. PMID: 29477379 Clinical Trial.
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.
Leivas A, Risueño RM, Guzmán A, Sánchez-Vega L, Pérez M, Megías D, Fernández L, Alonso R, Pérez-Martínez A, Rapado I, Martínez-López J. Leivas A, et al. Cancer Immunol Immunother. 2021 Oct;70(10):2911-2924. doi: 10.1007/s00262-021-02901-y. Epub 2021 Mar 10. Cancer Immunol Immunother. 2021. PMID: 33693963 Free PMC article.
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, Graña-Castro O, Fernández L, Carreño-Tarragona G, Pérez M, Megías D, Paciello ML, Sánchez-Pina J, Pérez-Martínez A, Lee DA, Powell DJ Jr, Río P, Martínez-López J. Leivas A, et al. Blood Cancer J. 2021 Aug 14;11(8):146. doi: 10.1038/s41408-021-00537-w. Blood Cancer J. 2021. PMID: 34392311 Free PMC article.
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
Paiva B, Gutiérrez NC, Chen X, Vídriales MB, Montalbán MÁ, Rosiñol L, Oriol A, Martínez-López J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Pérez JJ, Fernández-Redondo E, de Arriba F, Palomera L, Bengoechea E, Terol MJ, de Paz R, Martin A, Hernández J, Orfao A, Lahuerta JJ, Bladé J, Pandiella A, Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative. Paiva B, et al. Leukemia. 2012 Aug;26(8):1862-9. doi: 10.1038/leu.2012.42. Epub 2012 Feb 15. Leukemia. 2012. PMID: 22333880
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B, Vídriales MB, Rosiñol L, Martínez-López J, Mateos MV, Ocio EM, Montalbán MÁ, Cordón L, Gutiérrez NC, Corchete L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Granell M, Gorosquieta A, Alegre A, Orfao A, Lahuerta JJ, Bladé J, San Miguel JF; Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group. Paiva B, et al. Leukemia. 2013 Oct;27(10):2056-61. doi: 10.1038/leu.2013.166. Epub 2013 Jun 7. Leukemia. 2013. PMID: 23743858
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.
Rosiñol L, Oriol A, Teruel AI, de la Guía AL, Blanchard M, de la Rubia J, Granell M, Sampol M, Palomera L, González Y, Etxebeste M, Martínez-Martínez R, Hernández MT, de Arriba F, Alegre A, Cibeira M, Mateos M, Martínez-López J, Lahuerta JJ, San Miguel J, Bladé J. Rosiñol L, et al. Leukemia. 2017 Sep;31(9):1922-1927. doi: 10.1038/leu.2017.35. Epub 2017 Jan 23. Leukemia. 2017. PMID: 28111466 Clinical Trial.
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.
Campa D, Martino A, Macauda A, Dudziński M, Suska A, Druzd-Sitek A, Raab MS, Moreno V, Huhn S, Butrym A, Sainz J, Szombath G, Rymko M, Marques H, Lesueur F, Vangsted AJ, Vogel U, Kruszewski M, Subocz E, Buda G, Iskierka-Jażdżewska E, Ríos R, Merz M, Schöttker B, Mazur G, Perrial E, Martinez-Lopez J, Butterbach K, García Sanz R, Goldschmidt H, Brenner H, Jamroziak K, Reis RM, Kadar K, Dumontet C, Wątek M, Haastrup EK, Helbig G, Jurczyszyn A, Jerez A, Varkonyi J, Barington T, Grzasko N, Zaucha JM, Andersen V, Zawirska D, Canzian F. Campa D, et al. Leuk Lymphoma. 2019 Jul;60(7):1803-1811. doi: 10.1080/10428194.2018.1551536. Epub 2019 Jan 11. Leuk Lymphoma. 2019. PMID: 30633655
751 results